跳转至内容
Merck
CN
  • Modeling early pathophysiological phenotypes of diabetic retinopathy in a human inner blood-retinal barrier-on-a-chip.

Modeling early pathophysiological phenotypes of diabetic retinopathy in a human inner blood-retinal barrier-on-a-chip.

Nature communications (2024-02-15)
Thomas L Maurissen, Alena J Spielmann, Gabriella Schellenberg, Marc Bickle, Jose Ricardo Vieira, Si Ying Lai, Georgios Pavlou, Sascha Fauser, Peter D Westenskow, Roger D Kamm, Héloïse Ragelle
摘要

Diabetic retinopathy (DR) is a microvascular disorder characterized by inner blood-retinal barrier (iBRB) breakdown and irreversible vision loss. While the symptoms of DR are known, disease mechanisms including basement membrane thickening, pericyte dropout and capillary damage remain poorly understood and interventions to repair diseased iBRB microvascular networks have not been developed. In addition, current approaches using animal models and in vitro systems lack translatability and predictivity to finding new target pathways. Here, we develop a diabetic iBRB-on-a-chip that produces pathophysiological phenotypes and disease pathways in vitro that are representative of clinical diagnoses. We show that diabetic stimulation of the iBRB-on-a-chip mirrors DR features, including pericyte loss, vascular regression, ghost vessels, and production of pro-inflammatory factors. We also report transcriptomic data from diabetic iBRB microvascular networks that may reveal drug targets, and examine pericyte-endothelial cell stabilizing strategies. In summary, our model recapitulates key features of disease, and may inform future therapies for DR.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
单克隆抗S-100(β-亚基) 小鼠抗, clone SH-B1, ascites fluid
Sigma-Aldrich
抗IV型胶原蛋白 α2链抗体(克隆23IIC3), ascites fluid, clone 23IIC3, Chemicon®